Vor Biopharma Inc
VOR14.520USD
+1.030+7.64%
Market hours （ET）Quotes delayed by 15 min
131.07MMarket Cap
LossP/E TTM
More Details of Vor Biopharma Inc Company
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Vor Biopharma Inc Info
Ticker SymbolVOR
Company nameVor Biopharma Inc
IPO dateFeb 05, 2021
CEOKress (Jean-Paul)
Number of employees159
Security typeOrdinary Share
Fiscal year-endFeb 05
Address500 Boylston Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16176556580
Websitehttps://www.vorbio.com/
Ticker SymbolVOR
IPO dateFeb 05, 2021
CEOKress (Jean-Paul)
Company Executives of Vor Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
1.00
-694137.00%
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Sarah Reed
Ms. Sarah Reed
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
1.00
-694137.00%
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 23
Updated: Tue, Dec 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.10%
Forbion Capital Partners
10.11%
Frazier Life Sciences Management, L.P.
6.31%
Paradigm BioCapital Advisors LP
4.89%
Great Point Partners, LLC
3.45%
Other
60.14%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.10%
Forbion Capital Partners
10.11%
Frazier Life Sciences Management, L.P.
6.31%
Paradigm BioCapital Advisors LP
4.89%
Great Point Partners, LLC
3.45%
Other
60.14%
Shareholder Types
Shareholders
Proportion
Venture Capital
26.76%
Hedge Fund
9.12%
Private Equity
6.31%
Corporation
3.31%
Investment Advisor
1.28%
Research Firm
0.13%
Investment Advisor/Hedge Fund
0.12%
Bank and Trust
0.08%
Individual Investor
0.06%
Other
52.84%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
159
15.68M
43.82%
+11.76M
2025Q3
155
2.91M
42.56%
-894.32K
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
5.40M
15.1%
+3.06M
+130.46%
Dec 18, 2025
Forbion Capital Partners
3.62M
10.11%
+3.24M
+852.84%
Dec 18, 2025
Frazier Life Sciences Management, L.P.
2.26M
6.31%
+2.26M
--
Dec 18, 2025
Paradigm BioCapital Advisors LP
1.75M
4.89%
+1.75M
--
Nov 11, 2025
Great Point Partners, LLC
1.23M
3.45%
+1.23M
--
Dec 10, 2025
Reprogrammed Interchange LLC
1.17M
3.26%
-472.15K
-28.81%
Oct 21, 2025
VR Adviser, LLC
499.97K
1.4%
+499.97K
--
Sep 30, 2025
Fidelity Management & Research Company LLC
232.96K
0.65%
+132.18K
+131.14%
Sep 30, 2025
Ariose Capital Management Limited
110.17K
0.31%
+110.17K
--
Sep 30, 2025
The Vanguard Group, Inc.
105.19K
0.29%
+9.41K
+9.82%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Health Innovation Active ETF
0.17%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
View more
iShares Health Innovation Active ETF
Proportion0.17%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 17, 2025
Merger
20→1
Date
Type
Ratio
Sep 17, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Vor Biopharma Inc?
The top five shareholders of Vor Biopharma Inc are:
RA Capital Management, LP holds 5.40M shares, accounting for 15.10% of the total shares.
Forbion Capital Partners holds 3.62M shares, accounting for 10.11% of the total shares.
Frazier Life Sciences Management, L.P. holds 2.26M shares, accounting for 6.31% of the total shares.
Paradigm BioCapital Advisors LP holds 1.75M shares, accounting for 4.89% of the total shares.
Great Point Partners, LLC holds 1.23M shares, accounting for 3.45% of the total shares.
RA Capital Management, LP holds 5.40M shares, accounting for 15.10% of the total shares.
Forbion Capital Partners holds 3.62M shares, accounting for 10.11% of the total shares.
Frazier Life Sciences Management, L.P. holds 2.26M shares, accounting for 6.31% of the total shares.
Paradigm BioCapital Advisors LP holds 1.75M shares, accounting for 4.89% of the total shares.
Great Point Partners, LLC holds 1.23M shares, accounting for 3.45% of the total shares.
What are the top three shareholder types of Vor Biopharma Inc?
The top three shareholder types of Vor Biopharma Inc are:
RA Capital Management, LP
Forbion Capital Partners
Frazier Life Sciences Management, L.P.
RA Capital Management, LP
Forbion Capital Partners
Frazier Life Sciences Management, L.P.
How many institutions hold shares of Vor Biopharma Inc (VOR)?
As of 2025Q4, 159 institutions hold shares of Vor Biopharma Inc, with a combined market value of approximately 15.68M, accounting for 43.82% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 1.27%.
What is the biggest source of revenue for Vor Biopharma Inc?
In --, the -- business generated the highest revenue for Vor Biopharma Inc, amounting to -- and accounting for --% of total revenue.
